WORCESTER, Mass. and TORONTO, July 23, 2013 /PRNewswire/ -- Generex Biotechnology Corporation ( www.generex.com) (OTCBB: GNBT) today confirmed that it will be hosting a conference call with members of the Antigen Express, Inc. ( www.antigenexpress.com) Scientific Advisory Board on Wednesday, August 14, 2013 at 10 a.m. EDT. Call-in particulars will be announced prior to the call. The call will include a discussion of the on-going Phase II clinical trial of the Antigen Express AE37 breast cancer vaccine and the Antigen Express Ii-Key technology platform in the context of current breast cancer treatments and the industry focus on immunotherapeutic approaches to the treatment of cancer, as highlighted at the June 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). The call will feature the following members of the Antigen Express Scientific Advisory Board:
Dr. Gary H. Lyman, MD, MPH, FACP, FRCP (Edin), FASCO;
Dr. Gabriel N. Hortobagyi, MD, FACP;
Dr. Ian Krop, MD, PhD;
Dr. Keith L. Knutson, PhD;
Dr. James J. Mule, PhD;
Dr. Hope S. Rugo, MD; and
Dr. Samuel Jacobs, MD.
In addition, Dr. Elizabeth Mittendorf, MD, PhD, the Principal Investigator on the Antigen Express AE37 breast cancer vaccine Phase II trial, will participate on the panel. "We are pleased to bring together this panel of key opinion leaders to share their insights into the burgeoning research on immunotherapeutic approaches to the treatment of cancer, where scientists are seeking to enhance the immune system to combat cancer," commented Mark Fletcher, Generex's President & Chief Executive Officer. "Recent announcements by Merck and Bristol-Myers Squibb of favourable clinical trial data suggest that immunotherapeutic drugs may significantly impact the treatment of cancer. We look forward to additional data from the Antigen Express AE37 breast cancer vaccine trial this fall as we seek Phase III partnership opportunities in the context of the industry focus on immunotherapeutic treatments of cancer." The Antigen Express AE37 vaccine is designed to stimulate the immune system to target HER2 on breast cancer cells at low levels independent of immune type of the person. AE37 targets an early breast cancer patient population of unmet need several times larger than those treated with Herceptin. In particular, while Herceptin is approved for use in roughly 25% of early stage breast cancer patients with high expression of HER2, it is not approved for the larger group of women (50% of women with early breast cancer) who have lower levels of expression of the target for Herceptin (HER2). Rather than attacking HER2 cancer cells directly as does Herceptin, AE37 works by stimulating the immune system to recognize HER2. The greater sensitivity of the immune system can thereby recognize and kill cancer cells in this larger low HER2 expressing early breast cancer population. An additional potential advantage is that the immunological memory induced by AE37 means the immune system may continue to scan for and kill HER2 cancer cells long after AE37 treatment has been completed.